Fundz
Real-time · AI · Cross-signal

Bluejay Therapeutics just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on Bluejay Therapeutics, plus every funding round, exec hire, and M&A move that follows, each with verified, ICP-ranked contacts.

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Get the full Deep Dive on Bluejay Therapeutics — free.

We'll email your report. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.
✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.
✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.
✕Clay enriches lists you built — No live signal of its own, no who or when.
✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.
Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Bluejay Therapeutics secures $182M in a Series C financing to propel clinical pipeline.

RECENTLY ACQUIREDMay 09, 2024•about 2 years ago

Amount Raised

$182 Million

Round Type

series c

San MateoInformation Technology

Investors

Unicorn CapitalHbm Healthcare InvestmentsArkin Bio VenturesOctagon CapitalRiver Vest Venture PartnersNovo HoldingsWellington ManagementT. Rowe PriceRa Capital ManagementFrazier Life Sciences

Description

Bluejay Therapeutics has successfully closed a $182 million Series C financing round, co-led by Frazier Life Sciences and a life science focused institutional investment firm. The funding will accelerate the clinical development of BJT-778 for the treatment of chronic hepatitis D (HDV) and support the progression of additional promising candidates in Bluejay's robust pipeline for the treatment of chronic hepatitis B.

Company Information

Company

Bluejay Therapeutics

Location

951 Mariners Island Blvd., Suite 300

San Mateo, California, United States

About

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Bluejay Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Bluejay Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan